-
1
-
2
-
3Academic Journal
Συγγραφείς: Шавкатовна, Маликова Малика, Сайидович, Раупов Фарход
Πηγή: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 4 No. 2 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 120-123 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 4 № 2 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 120-123 ; 2181-3469
Θεματικοί όροι: методы дренажного лечения, острая бактериальная деструкция легких, рациональная медикаментозная терапия
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Συγγραφείς: Дога, А.В., Ободова, К.В.
Πηγή: FYODOROV JOURNAL OF OPHTHALMIC SURGERY ; No. 1 (2025): FYODOROV JOURNAL OF OPHTHALMIC SURGERY; 103-114 ; ОФТАЛЬМОХИРУРГИЯ; № 1 (2025): Офтальмохирургия; 103-114 ; 2312-4970 ; 0235-4160
Θεματικοί όροι: первичная открытоугольная глаукома, медикаментозная терапия, селективная лазерная трабекулопластика, внутриглазное давление, комплаенс, primary open-angle glaucoma, drug therapy, selective laser trabeculoplasty, intraocular pressure, compliance
Περιγραφή αρχείου: application/pdf
-
5
-
6
-
7Academic Journal
Συγγραφείς: Zh. D. Kobalava, A. O. Konradi, S. V. Nedogoda, E. V. Shlyakhto, G. P. Arutyunov, E. I. Baranova, O. L. Barbarash, N. V. Bobkova, S. A. Boytsov, M. G. Bubnova, T. V. Vavilova, S. V. Villevalde, A. S. Galyavich, M. G. Glezer, E. N. Grineva, Yu. I. Grinstein, O. M. Drapkina O. M.,, Yu. V. Zhernakova, N. E. Zvartau, O. B. Irtyuga, O. A. Kislyak, N. A. Koziolova, E. D. Kosmacheva, Yu. V. Kotovskaya Yu. V.,, R. A. Libis, Yu. M. Lopatin, D. V. Nebiridze, A. O. Nedoshivin, S. Yu. Nikulina, O. D. Ostroumova, E. V. Oschepkova, L. G. Ratova, A. S. Salasiuk, V. V. Skibitsky, O. N. Tkacheva, E. A. Troitskaya, I. E. Chazova, A. I. Chesnikova, G. A. Chumakova, S. A. Shalnova, M. V. Shestakova, S. S. Yakushin, S. N. Yanishevsky
Πηγή: Российский кардиологический журнал, Vol 29, Iss 9 (2024)
Θεματικοί όροι: артериальная гипертензия, гипертоническая болезнь, классификация артериальной гипертензии, артериальное давление, рекомендации, измерение артериального давления, целевые значения артериального давления, медикаментозная терапия артериальной гипертензии, гипертонический криз, сердечно-сосудистый риск, сердечно-сосудистые заболевания, Diseases of the circulatory (Cardiovascular) system, RC666-701
Περιγραφή αρχείου: electronic resource
Relation: https://russjcardiol.elpub.ru/jour/article/view/6117; https://doaj.org/toc/1560-4071; https://doaj.org/toc/2618-7620
Σύνδεσμος πρόσβασης: https://doaj.org/article/6caaf5be46cc4ec290eb2b4753793051
-
8Dissertation/ Thesis
Συγγραφείς: Akhmetshina, E. A.
Συνεισφορές: Гусев, В. В., Gusev, V. V., УрФУ. Уральский гуманитарный институт, Кафедра клинической психологии и психофизиологии
Θεματικοί όροι: REHABILITATION, ALTERNATIVE PHARMACOLOGICAL METHODS, МАГИСТЕРСКАЯ ДИССЕРТАЦИЯ, MASTER'S THESIS, BALANCE DISORDERS, РАССТРОЙСТВА РАВНОВЕСИЯ, ИШЕМИЧЕСКИЙ ИНСУЛЬТ, НЕМЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ, КОГНИТИВНЫЕ НАРУШЕНИЯ, COGNITIVE IMPAIRMENTS, DRUG THERAPY, АЛЬТЕРНАТИВНЫЕ ФАРМАКОЛОГИЧЕСКИЕ МЕТОДЫ, ISCHEMIC STROKE, РЕАБИЛИТАЦИЯ, NON-DRUG THERAPY, МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://elar.urfu.ru/handle/10995/145401
-
9Academic Journal
Συγγραφείς: Брыкало Владимир Андреевич, ФГБОУ ВО «Донской государственный технический университет», Vladimir A. Brykalo, Don State Technical University, Чистова Виктория Александровна, Viktoriia A. Chistova
Πηγή: Psychological and Pedagogical Research – Tula Region; 209-211 ; Психолого-педагогические исследования – Тульскому региону; 209-211
Θεματικοί όροι: психотерапия, агрессивное поведение, формы агрессии, психологические аспекты, когнитивно-поведенческая терапия, диагностика агрессии, коррекция агрессии, социальные факторы агрессии, фрустрационно-агрессивная теория, медикаментозная терапия
Περιγραφή αρχείου: text/html
Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907830-36-3; https://phsreda.com/e-articles/10611/Action10611-111887.pdf; Волкова Л.А. Причины криминально-агрессивного поведения подростков / Л.А. Волкова // Среднее профессиональное образование. – 2011. – №8. – С. 70–72.; Кривцова С.В. Травля в школе: есть ли выход? / С.В. Кривцова // Православное образование. – 2015. – №4/14. – С. 85–91.; https://phsreda.com/article/111887/discussion_platform
-
10Academic Journal
Συγγραφείς: A. Yu. Anisimov, Yu. A. Anisimov, А. Ю. Анисимов, Ю. А. Анисимов
Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 13, № 3 (2024); 427-435 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 13, № 3 (2024); 427-435 ; 2541-8017 ; 2223-9022
Θεματικοί όροι: вазоактивные препараты, refractory variceal bleeding, endoscopic stenting, drug therapy, vasoactive drugs, рефрактерное варикозное кровотечение, эндоскопическое стентирование, медикаментозная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.jnmp.ru/jour/article/view/1929/1485; https://www.jnmp.ru/jour/article/view/1929/1620; Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, et al. Vapreotide Study Group. Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol. 2017;51(5):446–453. PMID: 27779613 https://doi.org/10.1097/MCG.0000000000000733; Escorsell À, García-Pagán JC, Bosch J. Esophageal Stents for Acute Variceal Bleeding: Expanding the Possibilities. Dig Dis Sci. 2018;63(2):275–276. PMID: 29255994 https://doi.org/10.1007/s10620-017-4854-x; Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58(1):45–50. PMID: 22940408 https://doi.org/10.1016/j.jhep.2012.08.020; Шерцингер А.Г., Чжао А.В., Ивашкин В.Т., Маевская М.В., Павлов Ч. С., Верткин А.Л., и др. Лечение кровотечений из варикозно расширенных вен пищевода и желудка. Анналы хирургической гепатологии. 2013;18(3):110–129.; de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. PMID: 26047908 https://doi.org/10.1016/j.jhep.2015.05.022; Манукьян Г.В., Шерцингер А.Г., Жигалова С.Б., Семенова Т.С., Мартиросян Р.А. Первичная профилактика кровотечений из варикозно расширенных вен пищевода и желудка у больных портальной гипертензией (обзор литературы). Анналы хирургической гепатологии. 2016;21(2):93–104. https://doi.org/10.16931/1995-5464.2016293-104; de Mattos ÂZ, Terra C, Farias AQ, Bittencourt PL; Alliance of Brazilian Centers for Cirrhosis Care–the ABC Group. Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies. World J Gastrointest Endosc. 2021;13(12):628–637. PMID: 35070024 https://doi.org/10.4253/wjge.v13.i12.628; Zia HA, Aby ES, Rabiee A. An Update on the Management of Esophageal Variceal Hemorrhage. Clin Liver Dis (Hoboken). 2021;18(4):179–183. PMID: 34745574 https://doi.org/10.1002/cld.1108; Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig. 1994;72(9):653–659. PMID: 7849442 https://doi.org/10.1007/BF00212982; Ерамишанцев А.К., Шерцингер А.Г., Киценко Е.А. Портальная гипертензия. В кн.: Клиническая хирургия: национальное руководство: в 3-х т. Т.2. Москва: ГЭОАТР-Медиа; 2009. с. 626–665.; De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–176. PMID: 15925423 https://doi.org/10.1016/j.jhep.2005.05.009; Реброва О.Ю. Статистический анализ медицинских данных: применение пакета прикладных программ STATISTICA. Москва: Медиа Сфера; 2006.; Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958;53(282):457–481. https://doi.org/10.2307/2281868; Анисимов А.Ю., Логинов А.В., Ибрагимов Р.А., Анисимов А.А. Эндоскопический гемостаз саморасширяющимися нитиноловыми стентами (обзор литературы). Анналы хирургической гепатологии. 2020;25(1):94–105. https://doi.org/10.16931/1995-5464.2020194-105; de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. PMID: 35120736 https://doi.org/10.1016/j.jhep.2022.03.024; Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–335. PMID: 27786365 https://doi.org/10.1002/hep.28906; Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, et al. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(48):e13437. PMID: 30508958 https://doi.org/10.1097/MD.0000000000013437; Ioannou GN, Doust J, Rockey DC. Systematic review: Terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther. 2003;17(1):53–64. PMID: 12492732 https://doi.org/10.1046/j.1365-2036.2003.01356.x; Dell’Era A, de Franchis R. Iannuzzi F. Acute variceal bleeding: Pharmacological treatment and primary/secondary prophylaxis. Best Pract Res Clin Gastroenterol. 2008;22(2):279–294. PMID: 18346684 https://doi.org/10.1016/j.bpg.2007.11.001; Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, et al. Meta-analysis: Vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267–1278. PMID: 22486630 https://doi.org/10.1111/j.1365-2036.2012.05088.x; Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60(3):954–963. PMID: 24415445 https://doi.org/10.1002/hep.27006; Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev. 2003;(1):CD002147. PMID: 12535432 https://doi.org/10.1002/14651858.CD002147; Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–938. PMID: 17879356 https://doi.org/10.1002/hep.21907; Jenkins SA, Baxter JN, Corbett WA, Shields R. The effects of somatostatin analogue SMS 201-995 on hepatic hemodynamics in the cirrhotic rat. Br J Surg. 1985;72(11):864–867. PMID: 2866012 https://doi.org/10.1002/bjs.1800721105; Christiansen J, Ottenjann R, Von Arx F. Placebo-controlled trial with the somatostatin analogue SMS 201-995 in peptic ulcer. Gastroenterology. 1989;97(3):568–574. PMID: 2666249 https://doi.org/10.1016/0016-5085(89)90626-4; Hung TH, Tsai CC, TsenK GC, Hsieh YH, Tseng CW. No mortality difference following treatment with terlipressin or somatostatin in cirrhotic patients with gastric variceal hemorrhage. Saudi J Gastroenterol. 2016;22(3):220–225. PMID: 27184641 https://doi.org/10.4103/1319-3767.182458; https://www.jnmp.ru/jour/article/view/1929
-
11Academic Journal
Συγγραφείς: E. V. Pronin, T. M. Alexeeva, V. S. Pronin, M. B. Antsiferov, Е. В. Пронин, Т. М. Алексеева, В. С. Пронин, М. Б. Анциферов
Πηγή: Meditsinskiy sovet = Medical Council; № 16 (2024); 193-205 ; Медицинский Совет; № 16 (2024); 193-205 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: предикторы эффективности лечения, drug therapy, somatostatin receptor ligands, pasireotide, precision medicine, predictors of treatment efficacy, медикаментозная терапия, аналоги соматостатина, пасиреотид, прецизионная медицина
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8627/7576; Sampedro-Nuñez M, Herrera-Martínez AD, Ibáñez-Costa A, Rivero-Cortés E, Venegas E, Robledo M et al. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study. Eur J Endocrinol. 2024;190(6):421–433. https://doi.org/10.1093/ejendo/lvae045.; Vilar L, Naves LA, Martins MRA, Ribeiro-Oliveira A Jr. “Micromegaly”: Acromegaly with apparently normal GH, an entity on its own? Best Pract Res Clin Endocrinol Metab. 2024;38(3):101878. https://doi.org/10.1016/j.beem.2024.101878.; Gliga MC, Tătăranu LG, Popescu M, Chinezu L, Paşcanu MI. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review. Rom J Morphol Embryol. 2023;64(1):25–33. https://doi.org/10.47162/RJME.64.1.03.; Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Atutxa A et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019;23(5):3088–3096. https://doi.org/10.1111/jcmm.13851.; Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6–26. https://doi.org/10.1007/s12022-022-09703-7.; Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804–826. https://doi.org/10.1016/S2213-8587(22)00244-3.; Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. 2016;58(11):1057–1065. https://doi.org/10.1007/s00234-016-1728-4.; Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7–22. https://doi.org/10.1007/s11102-023-01360-1.; Clemmons DR, Bidlingmaier M. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. Front Endocrinol. 2023;14:1266339. https://doi.org/10.3389/fendo.2023.1266339.; Ershadinia N, Tritos NA. Diagnosis and Treatment of Acromegaly: An Update. Mayo Clin Proc. 2022;97(2):333–346. https://doi.org/10.1016/j.mayocp.2021.11.007.; Coopmans EC, van der Lely AJ, Neggers SJCMM. Approach to the Patient With Treatment-resistant Acromegaly. J Clin Endocrinol Metab. 2022;107(6):1759–1766. https://doi.org/10.1210/clinem/dgac037.; Shimon I. Real-world value of cabergoline in the treatment of acromegaly. Best Pract Res Clin Endocrinol Metab. 2024;38(4):101887. https://doi.org/10.1016/j.beem.2024.101887.; Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77–79. https://doi.org/10.1126/science.179.4068.77.; Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016;23(12):R551–R566. https://doi.org/10.1530/ERC-16-0151.; Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci. 2020;21(5):1682. https://doi.org/10.3390/ijms21051682.; Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–252. https://doi.org/10.1016/j.yfrne.2013.07.005.; Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol. 2008;286(1-2):192–198. https://doi.org/10.1016/j.mce.2007.11.024.; Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol. 2014;45(1):71–77. https://doi.org/10.1016/j.humpath.2013.08.007.; Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 1994;79(3):724–729. https://doi.org/10.1210/jcem.79.3.7521350.; Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247–271. https://doi.org/10.1210/er.2010-0002.; Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988;9(4):417–436. https://doi.org/10.1210/edrv-9-4-417.; Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin. 2009;25(12):2989–2999. https://doi.org/10.1185/03007990903328959.; Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223-R240. https://doi.org/10.1530/JME-14-0011.; Grasso LF, Auriemma RS, Pivonello R, Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf. 2015;14(8):1213–1226. https://doi.org/10.1517/14740338.2015.1059817.; Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–108. https://doi.org/10.1007/s11102-017-0791-0.; Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L et al. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 2021;24(6):943–953. https://doi.org/10.1007/s11102-021-01163-2.; Bolanowski M, Kałużny M, Witek P, Jawiarczyk-Przybyłowska A. Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord. 2022;23(3):601–620. https://doi.org/10.1007/s11154-022-09710-3.; Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1-2):69–74. https://doi.org/10.1016/j.mce.2007.09.006.; Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781–2789. https://doi.org/10.1210/jc.2009-2272.; Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19(5):536–543. https://doi.org/10.1007/s11102-016-0734-1.; Periferakis A, Tsigas G, Periferakis AT, Tone CM, Hemes DA, Periferakis K et al. Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias. Curr Issues Mol Biol. 2024;46(9):9721–9759. https://doi.org/10.3390/cimb46090578.; Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 2014;17(2):132–140. https://doi.org/10.1007/s11102-013-0478-0.; Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799. https://doi.org/10.1210/jc.2013-2480.; Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884. https://doi.org/10.1016/S2213-8587(14)70169-X.; Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X et al. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. J Clin Endocrinol Metab. 2023;108(12):e1571–e1579. https://doi.org/10.1210/clinem/dgad378.; Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center. J Endocrinol Invest. 2024;47(8):1887–1901. https://doi.org/10.1007/s40618-023-02299-7.; Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Luźniak A, Jawiarczyk-Przybyłowska A, Kałużny M. The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Front Endocrinol. 2021;12:633944. https://doi.org/10.3389/fendo.2021.633944.; Urbani C, Dassie F, Zampetti B, Mioni R, Maffei P, Cozzi R, Bogazzi F. Reallife data of Pasireotide LAR in acromegaly: a long-term follow-up. J Endocrinol Invest. 2024;47(7):1733–1741. https://doi.org/10.1007/s40618-023-02275-1.; Favero V, Zampetti B, Carioni EI, Dalino Ciaramella P, Grossrubatscher E, Dallabonzana D et al. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study. Front Endocrinol. 2024;15:1344728. https://doi.org/10.3389/fendo.2024.1344728.; Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes ML, Tabarin A. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect. 2019;8(10):1383–1394. https://doi.org/10.1530/EC-19-0332.; Shimon I, Adnan Z, Gorshtein A, Baraf L, Saba Khazen N, Gershinsky M et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62(2):448–455. https://doi.org/10.1007/s12020-018-1690-5.; Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, Neggers SJCMM. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). J Clin Endocrinol Metab. 2018;103(2):586–595. https://doi.org/10.1210/jc.2017-02017.; Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E et al. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer. 2024;31(7):e240043. https://doi.org/10.1530/ERC-24-0043.; Coopmans EC, van der Lely AJ, Schneiders JJ, Neggers SJCMM. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet Diabetes Endocrinol. 2019;7(6):425–426. https://doi.org/10.1016/S2213-8587(19)30113-5.; Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely AJ et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605. https://doi.org/10.1530/EJE-19-084.; Dabbous Z, Rohani Z, Abdalrubb AK, Alkailani Y, Pivonello R, Elhadd T. Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. JCEM Case Rep. 2024;2(8):luae142. https://doi.org/10.1210/jcemcr/luae142.; Slagboom TNA, van Bunderen CC, De Vries R, Bisschop PH, Drent ML. Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary. 2023;26(4):319–332. https://doi.org/10.1007/s11102-023-01322-7.; Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM. How to Position Pasireotide LAR Treatment in Acromegaly. J Clin Endocrinol Metab. 2019;104(6):1978–1988. https://doi.org/10.1210/jc.2018-01979.; Stelmachowska-Banaś M, Czajka-Oraniec I, Tomasik A, Zgliczyński W. Realworld experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary. 2022;25(1):180–190. https://doi.org/10.1007/s11102-021-01185-w.; Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, Feldt-Rasmussen U. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues – Observations in two patients with acromegaly and severe headache. Growth Horm IGF Res. 2015;25(5):262–267. https://doi.org/10.1016/j.ghir.2015.07.003.; Amarù J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, et al. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. Cancers. 2021;13(8):1816. https://doi.org/10.3390/cancers13081816.; De Fano M, Falorni A, Malara M, Porcellati F, Fanelli CG. Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review. Diabetes Metab Syndr Obes. 2024;17:2761–2774. https://doi.org/10.2147/DMSO.S466328.; Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenický P, Chanson P. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. 2022;11(12):e220296. https://doi.org/10.1530/EC-22-0296.; Störmann S, Meyhöfer SM, Groener JB, Faust J, Schilbach K, Seufert J, Vergès B. Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement. Front Endocrinol. 2024;15:1348990. https://doi.org/10.3389/fendo.2024.1348990.; Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P et al. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol. 2024;15:1250822. https://doi.org/10.3389/fendo.2024.1250822.; Zaina A, Grober Y, Abid A, Arad E, Golden E, Badarny S. Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review. Endocrine. 2021;73(1):65–70. https://doi.org/10.1007/s12020-021-02718-w.; Giampietro A, Menotti S, Chiloiro S, Pontecorvi A, De Marinis L, Bianchi A. De-escalation treatment with pasireotide for acromegaly: a long-term experience. Endocrine. 2023;80(3):505–510. https://doi.org/10.1007/s12020-023-03325-7.; Chiloiro S, Appetecchia M, Bianchi A, Costa D, De Acetis C, Gargiulo P et al. Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences. Drugs Context. 2024;13:2024-1-2. https://doi.org/10.7573/dic.2024-1-2.; Marques NV, Wildemberg LEA, Gadelha MR. Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly. Endocr Connect. 2023;12(10):e230155. https://doi.org/10.1530/EC-23-0155.; Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525–538. https://doi.org/10.1530/EJE-21-0239.; Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L et al. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. J Clin Endocrinol Metab. 2019;104(11):5478–5482. https://doi.org/10.1210/jc.2019-00825.; Lim DST, Fleseriu M. Personalized Medical Treatment of Patients With Acromegaly: A Review. Endocr Pract. 2022;28(3):321–332. https://doi.org/10.1016/j.eprac.2021.12.017.; Lu Y, Zhao Z, Wang J, Lv W, Lu L, Fu W, Li W. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. Medicine. 2018;97(41):e12784. https://doi.org/10.1097/MD.0000000000012784.; Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S. Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review. Front Oncol. 2022;12:916982. https://doi.org/10.3389/fonc.2022.916982.; Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L. Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best Pract Res Clin Endocrinol Metab. 2022;36(6):101684. https://doi.org/10.1016/j.beem.2022.101684.; Kasuki L, Gadelha MR. Innovative therapeutics in acromegaly. Best Pract Res Clin Endocrinol Metab. 2022;36(6):101679. https://doi.org/10.1016/j.beem.2022.101679.; Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16(4):490–498. https://doi.org/10.1007/s11102-012-0445-1.; Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241–250. https://doi.org/10.1530/EJE-15-0832.; Gliga MC, Chinezu L, Pascanu IM. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. Int J Mol Sci. 2024;25(16):8663. https://doi.org/10.3390/ijms25168663.; Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest. 2003;26(8 Suppl.):4–7. Available at: https://pubmed.ncbi.nlm.nih.gov/15233203.; Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest. 2013;36(1):38–43. https://doi.org/10.3275/8305.; Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO et al. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol. 2015;417:73–83. https://doi.org/10.1016/j.mce.2015.09.016.; Muhammad A, Coopmans EC, Gatto F, Franck SE, Janssen JAMJL, van der Lely AJ et al. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. J Clin Endocrinol Metab. 2019;104(3):915–924. https://doi.org/10.1210/jc.2018-01524.; Daly AF, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS et al. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect. 2019;8(4):367–377. https://doi.org/10.1530/EC-19-0004.; Wang M, Shen M, He W, Yang Y, Liu W, Lu Y et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J. 2016;63(9):819–834. https://doi.org/10.1507/endocrj.EJ16-0175.; Marques-Pamies M, Gil J, Valassi E, Hernández M, Biagetti B, Giménez-Palop O et al. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly. Front Endocrinol. 2023;14:1269787. https://doi.org/10.3389/fendo.2023.1269787.; Puig-Domingo M, Bernabéu I, Picó A, Biagetti B, Gil J, Alvarez-Escolá C et al. Pasireotide in the Personalized Treatment of Acromegaly. Front Endocrinol. 2021;12:648411. https://doi.org/10.3389/fendo.2021.648411.; Marques-Pamies M, Gil J, Jordà M, Puig-Domingo M. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly. Arch Med Res. 2023;54(8):102924. https://doi.org/10.1016/j.arcmed.2023.102924.; Marazuela M, Martínez-Hernandez R, Marques-Pamies M, Biagetti B, Araujo-Castro M, Puig-Domingo M. Predictors of biochemical response to somatostatin receptor ligands in acromegaly. Best Pract Res Clin Endocrinol Metab. 2024;38(4):101893. https://doi.org/10.1016/j.beem.2024.101893.; Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7.; Daly AF, Lysy PA, Desfilles C, Rostomyan L, Mohamed A, Caberg JH et al. GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer. 2016;23(3):161–170. https://doi.org/10.1530/ERC-15-0478.; Bhat SZ, Salvatori R. Current role of pasireotide in the treatment of acromegaly. Best Pract Res Clin Endocrinol Metab. 2024;38(4):101875. https://doi.org/10.1016/j.beem.2024.101875.
-
12Academic Journal
Συγγραφείς: M. N. Sinkova, L. K. Isakov, E. Yu. Plotnikova, O. L. Barbarash, М. Н. Синькова, Л. К. Исаков, Е. Ю. Плотникова, О. Л. Барбараш
Πηγή: Meditsinskiy sovet = Medical Council; № 16 (2024); 101-107 ; Медицинский Совет; № 16 (2024); 101-107 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: препараты SGLT2, optimal drug therapy, physical training, quality of life, SGLT2 drugs, оптимальная медикаментозная терапия, физические тренировки, качество жизни
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8617/7565; Синьков МА, Кочергин НА, Ганюков ВИ. Госпитальные результаты лечения больных острым коронарным синдромом без подъема сегмента ST по данным реальной клинической практики. Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(1):23–29. https://doi.org/10.17802/2306-1278-2019-8-1-23-29.; Несова АК, Рябов ВВ. Парадоксы острого коронарного синдрома без подъема сегмента ST в условиях реальной клинической практики. Российский кардиологический журнал. 2024;29(3):5623. https://doi.org/10.15829/1560-4071-2024-5623.; Алекян БГ, Бойцов СА, Маношкина ЕМ, Ганюков ВИ. Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016–2020 гг. Кардиология. 2021;61(12):4–15. https://doi.org/10.18087/cardio.2021.12.n1879.; Синькова МН, Исаков ЛК, Синьков МА, Плотникова ЕЮ, Гуляева ЕН. Новое в реабилитации больных с хронической сердечной недостаточностью, ассоциированной с сахарным диабетом 2-го типа. Медицинский совет. 2020;(14):40–47. https://doi.org/10.21518/2079-701X-2020-14-40-47.; Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMc1600827.; Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268.; Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.; Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389.; Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.; Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and metaanalysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X.; Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854. https://doi.org/10.1016/S2213-8587(19)30256-6.; Синькова МН, Исаков ЛК, Плотникова ЕЮ, Тарасов НИ. Влияние контролируемых физических тренировок на качество жизни больных хронической сердечной недостаточностью на фоне сахарного диабета 2-го типа. Дневник Казанской медицинской школы. 2018;(4):6–11. Режим доступа: https://dnevnik-kmsc.ru/kosmetologiya/item/556-vliyanie-kontroliruemykhfizicheskikh-trenirovok-na-kachestvo-zhizni-bolnykh-khronicheskojserdechnoj-nedostatochnostyu-na-fone-sakharnogo-diabeta-2-go-tipa.; Кобалава ЖД, Ешниязов НБ, Медовщиков ВВ, Хасанова ЭР. Сахарный диабет 2-го типа и сердечная недостаточность: инновационные возможности управления прогнозом. Кардиология. 2019;59(4):76–87. https://doi.org/10.18087/cardio.2019.4.10253.; Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Бойцов СА, Васюк ЮА и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083.; Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190.; Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397–1407. https://doi.org/10.1016/j.jacc.2021.01.044.; Дедов ИИ, Шестакова МВ, Майоров АЮ, Шамхалова МШ, Сухарева ОЮ, Галстян ГР и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4–102. https://doi.org/10.14341/DM12507.; McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.; Синькова МН, Пепеляева ТВ, Исаков ЛК, Тарасов НИ, Тепляков АТ. Отдаленные эффекты влияния омега-3 полиненасыщенных жирных кислот на течение ишемической болезни сердца у больных, перенесших инфаркт миокарда с подъемом сегмента st на фоне многососудистого стенозирующего атеросклероза коронарных артерий. Кардиоваскулярная терапия и профилактика. 2014;13(6):32–37. https://doi.org/10.15829/1728-8800-2014-6-32-37.; Radhoe SP, Veenis JF, Linssen GCM, van der Lee C, Eurlings LWM, Kragten H et al. Diabetes and treatment of chronic heart failure in a large real-world heart failure population. ESC Heart Fail. 2022;9(1):353–362. https://doi.org/10.1002/ehf2.13743.; Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–155. https://doi.org/10.1002/clc.23321.; Витт КН, Кужелева ЕА, Тукиш ОВ, Солдатенко МВ, Кондратьев МЮ, Огуркова ОН и др. Низкоинтенсивное воспаление как проявление коморбидности и фактор неблагоприятного клинического течения сердечной недостаточности с сохраненной фракцией выброса. Кардиоваскулярная терапия и профилактика. 2024;23(2):3847. https://doi.org/10.15829/1728-8800-2024-3847.; Акчурин РС, Алекян БГ, Аронов ДМ, Беленков ЮН, Бойцов СА, Болдуева СА и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. Режим доступа: https://russjcardiol.elpub.ru/jour/article/viewFile/4076/3082.; Ларина ВН, Скиба ИК, Ларин ВГ, Михайлусова МП, Скиба АС. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка на фоне сахарного диабета: общие механизмы и возможная тактика терапии. CardioСоматика. 2022;13(2):115–123. https://doi.org/10.17816/CS110912.; Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827–838. https://doi.org/10.1001/jama.2023.2020.; Акопян ЕС. Нагрузки в оздоровительной тренировке взрослых: допустимые величины и способы регулирования. Наука и спорт: современные тенденции. 2020;8(1):106–115. Режим доступа: https://cyberleninka.ru/article/n/nagruzki-v-ozdorovitelnoy-trenirovke-vzroslyh-dopustimyevelichiny-i-sposoby-regulirovaniya.; Манукян МА, Фальковская АЮ, Мордовин ВФ, Рябова ТР, Зюбанова ИВ, Гусакова АМ, Суслова ТЕ. Особенности хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка у больных резистентной артериальной гипертонией в сочетании с сахарным диабетом 2-го типа. Сахарный диабет. 2021;24(4):304–314. https://doi.org/10.14341/DM12732.; Качнов ВА, Тыренко ВВ, Кольцов АВ, Бологов СГ, Коцоева ОТ. Новый фенотип пациента с сердечной недостаточностью со «сверхнормальной фракцией выброса левого желудочка». Кардиологический вестник. 2023;18(3):16–22. https://doi.org/10.17116/Cardiobulletin20231803116.
-
13Academic Journal
Συγγραφείς: E. V. Pronin, V. S. Pronin, M. B. Antsiferov, A. V. Petryaykin, T. M. Alexeeva, A. M. Lapshina, L. S. Urusova, A. N. Khoruzhaya, S. M. Tamaeva, Е. В. Пронин, В. С. Пронин, М. Б. Анциферов, А. В. Петряйкин, Т. М. Алексеева, А. М. Лапшина, Л. С. Урусова, А. Н. Хоружая, С. М. Тамаева
Πηγή: Meditsinskiy sovet = Medical Council; № 6 (2024); 98-111 ; Медицинский Совет; № 6 (2024); 98-111 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: пэгвисомант, somatotrophic tumors, precision medicine, T2-weighted MRI, T1-weighted MRI, (T2-T1)-weighted MRI, drug therapy, first-generation somatostatin receptor ligands, pegvisomant, соматотрофные опухоли, прецизионная медицина, 2-й подтип соматостатиновых рецепторов, фиброзные тельца, Т2-взвешенные изображения, Т1-взвешенные изображения, (Т2-Т1)-взвешенные изображения, медикаментозная терапия, аналоги соматостатина 1-го поколения
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8273/7295; Asa SL, Kucharczyk W, Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017;24(3):C1–C4. https://doi.org/10.1530/erc-16-0496.; Lenders NF, Earls PE, Inder WJ, McCormack AI. The evolution in pituitary tumour classification: a clinical perspective. Endocr Oncol. 2023;3(1):e220079. https://doi.org/10.1530/EO-22-0079.; Asa SL. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. Endocr Pathol. 2021;32(2):222–227. https://doi.org/10.1007/s12022-021-09678-x.; Lee CH. Pituitary Neuroendocrine Tumor: Is It Benign or Malignant? Brain Tumor Res Treat. 2023;11(3):173–176. https://doi.org/10.14791/btrt.2023.0015.; Mete O, Wenig BM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol. 2022;16(1):123–142. https://doi.org/10.1007/s12105-022-01435-8.; Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary. 2021;24(2):192–206. https://doi.org/10.1007/s11102-020-01096-2.; Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol. 2020;31(4):330–336. https://doi.org/10.1007/s12022-020-09646-x.; Liu X, Dai C, Feng M, Li M, Chen G, Wang R. Diagnosis and treatment of refractory pituitary adenomas: a narrative review. Gland Surg. 2021;10(4):1499–1507. https://doi.org/10.21037/gs-20-873.; Akirov A, Asa SL, Amer L, Shimon I, Ezzat S. The Clinicopathological Spectrum of Acromegaly. J Clin Med. 2019;8(11):1962. https://doi.org/10.3390/jcm8111962.; Ferrés A, Reyes L, Di Somma A, Topczewski T, Mosteiro A, Guizzardi G et al. The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up. Cancers (Basel). 2022;15(1):267. https://doi.org/10.3390/cancers15010267.; Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7.; Remba-Shapiro I, Nachtigall LB. Treatment of acromegaly with oral octreotide. Best Pract Res Clin Endocrinol Metab. 2024:101888. https://doi.org/10.1016/j.beem.2024.101888.; Puig-Domingo M, Gil J, Sampedro-Nuñez M, Jordà M, Webb SM, Serra G et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27(6):375–389. https://doi.org/10.1530/ERC-18-0565.; Ku CR, Melnikov V, Zhang Z, Lee EJ. Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? Endocrinol Metab (Seoul). 2020;35(2):206–216. https://doi.org/10.3803/EnM.2020.35.2.206.; Kasuki L, Lamback E, Antunes X, Gadelha MR. Biomarkers of response to treatment in acromegaly. Expert Rev Endocrinol Metab. 2024;19(1):71–80. https://doi.org/10.1080/17446651.2023.2293107.; Găloiu S, Toma ID, Tănasie DI, Bărbulescu A, Baciu I, Niculescu DA et al. High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne). 2024;15:1348972. https://doi.org/10.3389/fendo.2024.1348972.; Gil J, Marques-Pamies M, Sampedro M, Webb SM, Serra G, Salinas I et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. Sci Rep. 2022;12(1):8979. https://doi.org/10.1038/s41598-022-12955-2.; Berton AM, Prencipe N, Bertero L, Baldi M, Bima C, Corsico M et al. Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. J Clin Med. 2022;12(1):25. https://doi.org/10.3390/jcm12010025.; Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525–538. https://doi.org/10.1530/EJE-21-0239.; Soukup J, Hornychova H, Manethova M, Michalova K, Michnova L, Popovska L et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J Cell Mol Med. 2021;25(5):2484–2492. https://doi.org/10.1111/jcmm.16173.; Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82–91. https://doi.org/10.1007/s12022-008-9029-z.; Asa SL, Ezzat S. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. J Clin Med. 2021;10(11):2254. https://doi.org/10.3390/jcm10112254.; Kasuki L, Gadelha MR. Innovative therapeutics in acromegaly. Best Pract Res Clin Endocrinol Metab. 2022;36(6):101679. https://doi.org/10.1016/j.beem.2022.101679.; Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely AJ et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605. https://doi.org/10.1530/EJE-19-0840.; Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973–4978. https://doi.org/10.1210/jc.2010-0573.; Kocak B, Durmaz ES, Kadioglu P, Polat Korkmaz O, Comunoglu N, Tanriover N et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731–2739. https://doi.org/10.1007/s00330-018-5876-2.; Liu CX, Wang SZ, Heng LJ, Han Y, Ma YH, Yan LF et al. Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics. J Comput Assist Tomogr. 2022;46(1):124–130. https://doi.org/10.1097/RCT.0000000000001249.; Tang Y, Xie T, Guo Y, Liu S, Li C, Liu T et al. Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas. World Neurosurg. 2024;182:e334–e343. https://doi.org/10.1016/j.wneu.2023.11.107.; Scânteie CL, Leucuţa DC, Ghervan C. The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI. Med Pharm Rep. 2021;94(4):425–433. https://doi.org/10.15386/mpr-1299.; Анциферов МБ, Петряйкин АВ, Алексеева ТМ, Пронин ЕВ, Хоружая АН, Тамаева СМ. Современные возможности опухоль-ориентированной диагностики и лечения акромегалии. Фарматека. 2023;(3):78–88. https://doi.org/10.18565/pharmateca.2023.3.78-88.; Marques-Pamies M, Gil J, Jordà M, Puig-Domingo M. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly. Arch Med Res. 2023;54(8):102924. https://doi.org/10.1016/j.arcmed.2023.102924.; Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K et al. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study. Growth Horm IGF Res. 2022;67:101502. https://doi.org/10.1016/j.ghir.2022.101502.; Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G et al. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly. Front Endocrinol (Lausanne). 2022;13:957301. https://doi.org/10.3389/fendo.2022.957301.; Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M et al. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Front Endocrinol (Lausanne). 2022;13:984877. https://doi.org/10.3389/fendo.2022.984877.; Giustina A, di Filippo L, Uygur MM, Frara S. Modern approach to resistant acromegaly. Endocrine. 2023;80(2):303–307. https://doi.org/10.1007/s12020-023-03317-7.; Pronin VS, Antsiferov MB, Alexeeva TM, Pronin EV. Using a Precision Approach to Optimize the Drug Therapy of Patients With Acromegaly Syndrome. In: Ahmad M (ed.). The Pituitary Gland – An Overview of Pathophysiology and Current Management Techniques. London: IntechOpen; 2023, pp. 25–44. https://doi.org/10.5772/intechopen.1001376.; Ezzat S, Caspar-Bell GM, Chik CL, Denis MC, Domingue MÈ, Imran SA et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019;25(4):379–393. https://doi.org/10.4158/EP-2018-0500.; Ezzat S, Wang R, Pintilie M, Asa SL. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. Oncotarget. 2017;8(2):3481–3494. https://doi.org/10.18632/oncotarget.13843.; Chiloiro S, De Marinis L. The immune microenviroment in somatotropinomas: from biology to personalized and target therapy. Rev Endocr Metab Disord. 2023;24(2):283–295. https://doi.org/10.1007/s11154-022-09782-1.; Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95(5):2334–2342. https://doi.org/10.1210/jc.2009-2197.; Nishioka H, Haraoka J, Akada K. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol (Oxf). 2003;59(6):768–772. https://doi.org/10.1046/j.1365-2265.2003.01921.x.; Gil J, Marques-Pamies M, Valassi E, García-Martínez A, Serra G, Hostalot C et al. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. Biomedicines. 2022;10(2):460. https://doi.org/10.3390/biomedicines10020460.; Gliga MC, Tătăranu LG, Popescu M, Chinezu L, Paşcanu MI. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review. Rom J Morphol Embryol. 2023;64(1):25–33. https://doi.org/10.47162/RJME.64.1.03.; Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C et al. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep. 2018;8(1):6173. https://doi.org/10.1038/s41598-018-24260-y.; Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66–E71. https://doi.org/10.1210/jc.2012-2609.; Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R. Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary. World Neurosurg. 2024. https://doi.org/10.1016/j.wneu.2024.02.115.; Gadelha MR, Kasuki L. Refractory somatotroph adenomas. Pituitary. 2023;26(3):266–268. https://doi.org/10.1007/s11102-023-01324-5.
-
14Academic Journal
Συγγραφείς: Aleksey N. Sumin, Anna V. Shcheglova, Yulia D. Medvedeva, Sergey V. Ivanov, Vasily V. Kashtalap, Olga L. Barbarash, Алексей Николаевич Сумин, Анна Викторовна Щеглова, Юлия Дмитриевна Медведева, Сергей Васильевич Иванов, Василий Васильевич Кашталап, Ольга Леонидовна Барбараш
Συνεισφορές: Работа выполнена при поддержке комплексной программы фундаментальных исследований СО РАН в рамках темы фундаментальных исследований НИИ комплексных проблем сердечно-сосудистых заболеваний № 0419-2022-0002 «Разработка инновационных моделей управления риска развития заболеваний системы кровообращения с учетом коморбидности на основе изучения фундаментальных, клинических, эпидемиологических механизмов и организационных технологий оказания медицинской помощи в промышленном регионе Сибири».
Πηγή: Complex Issues of Cardiovascular Diseases; Том 13, № 1 (2024); 129-137 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 13, № 1 (2024); 129-137 ; 2587-9537 ; 2306-1278
Θεματικοί όροι: Мультифокальный атеросклероз, Optimal drug therapy, Peripheral artery diseases, Multifocal atherosclerosis, Оптимальная медикаментозная терапия, Заболевания периферических артерий
Περιγραφή αρχείου: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/1460/885; Барбараш Л.С., Сумин А.Н., Безденежных А.В., Жучкова Е.А., Барбараш О.Л. Распространенность мультифокального атеросклероза у больных с ишемической болезнью сердца. Комплексные проблемы сердечно-сосудистых заболеваний. 2013;(3):4-11. doi:10.17802/2306-1278-2013-3-4-11; Иванов С.В., Сумин А.Н., Казачек Я.В., Филипьев Д.Е., Гусев С.М., Малышенко Е.С., Барбараш Л.С. Пути оптимизации результатов реваскуляризации у пациентов с мультифокальным атеросклерозом. Комплексные проблемы сердечно-сосудистых заболеваний. 2013;(3):26-35. doi:10.17802/2306-1278-2013-3-26-35; Sumin A.N., Shcheglova A.V., Ivanov S.V., Barbarash O.L. Long-Term Prognosis after Coronary Artery Bypass Grafting: The Impact of Arterial Stiffness and Multifocal Atherosclerosis. J Clin Med. 2022;11(15):4585. doi:10.3390/jcm11154585.; Smilowitz N.R., Cornwell M., Offerman E.J., Rockman C.B., Shah S.H., Newman J.D., Ruggles K., Voora D., Berger J.S. Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. Sci Rep. 2022;12(1):6718. doi:10.1038/s41598-022-10241-9.; Fowkes F.G., Rudan D., Rudan I., Aboyans V., Denenberg J.O., McDermott M.M., Norman P.E., Sampson U.K., Williams L.J., Mensah G.A., Criqui M.H. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-40. doi:10.1016/S0140-6736(13)61249-0.; Evans P., Sobieszczyk P., Eisenhauer A.C., Ostrowski S., Todoran T.M., Kinlay S. Risk of Mortality Related to Recurrent Limb Events After Endovascular Revascularization of the Superficial Femoral Artery for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. Am J Cardiol. 2023;205:425-430. doi:10.1016/j.amjcard.2023.07.172.; Boyd S., Dittman J.M., Tse W., Lavingia K.S., Amendola M.F. Modern Lower Extremity Bypass Outcomes by Anesthesia Type in the Veteran Population. Ann Vasc Surg. 2022;80:187-195. doi:10.1016/j.avsg.2021.08.028.; He J.J., Horns J.J., Kraiss L.W., Smith B.K., Griffin C.L., DeMartino R.R., Sarfati M.R., Brooke B.S. High-intensity statin therapy reduces risk of amputation and reintervention among patients undergoing lower extremity bypass for chronic limb-threatening ischemia. J Vasc Surg. 2023;77(2):497-505. doi:10.1016/j.jvs.2022.09.007.; Cai M., Xie Y., Bowe B., Gibson A.K., Zayed M.A., Li T., Al-Aly Z. Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Netw Open. 2021;4(1):e2033953. doi:10.1001/jamanetworkopen.2020.33953.; Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., De Carlo M., Debus S., Espinola-Klein C., Kahan T., Kownator S., Mazzolai L., Naylor A.R., Roffi M., Röther J., Sprynger M., Tendera M., Tepe G., Venermo M., Vlachopoulos C., Desormais I.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.; Saxon J.T., Safley D.M., Mena-Hurtado C., Heyligers J., Fitridge R., Shishehbor M., Spertus J.A., Gosch K., Patel M.R., Smolderen K.G. Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. J Am Heart Assoc. 2020;9(3):e012541. doi:10.1161/JAHA.119.012541.; Hua S., Isasi C.R., Kizer J.R., Matsushita K., Allison M.A., Tarraf W., Qi Q., Ponce S.G., Daviglus M., Kaplan R.C. Underuse of Cardiovascular Medications in Individuals With Known Lower Extremity Peripheral Artery Disease: HCHS/SOL. J Am Heart Assoc. 2020;9(16):e015451. doi:10.1161/JAHA.119.015451.; Барбараш Л.С., Сумин А.Н., Медведева Ю.Д., Корок Е.В. Сравнительное исследование результатов трехлетнего наблюдения у кардиологов и хирургов пациентов с облитерирующим атеросклерозом нижних конечностей. Рациональная Фармакотерапия в Кардиологии 2019;15(5):690-696. doi:10.20996/1819-6446-2019-15-5-690-696; Kumbhani D.J., Steg P.G., Cannon C.P., Eagle K.A., Smith S.C.Jr., Goto S., Ohman E.M., Elbez Y., Sritara P., Baumgartner I., Banerjee S., Creager M.A., Bhatt D.L.; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. doi:10.1093/eurheartj/ehu080.; Lo H.Y., Lin Y.S., Lin D.S., Lee J.K., Chen W.J. Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis. JAMA Netw Open. 2022;5(9):e2229706. doi:10.1001/jamanetworkopen.2022.29706.; Kim G.S., Seo J., Kim B.G., Jin M.N., Lee H.Y., Kim B.O., Byun Y.S. Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease. Yonsei Med J. 2022;63(4):333-341. doi:10.3349/ymj.2022.63.4.333.; Navar A.M., Kolkailah A.A., Gupta A., Gillard K.K., Israel M.K., Wang Y., Peterson E.D. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients. Circ Cardiovasc Qual Outcomes. 2023;16(8):533-543. doi:10.1161/CIRCOUTCOMES.122.009787.; Belur A.D., Shah A.J., Virani S.S., Vorla M., Kalra D.K. Role of Lipid-Lowering Therapy in Peripheral Artery Disease. J Clin Med. 2022;11(16):4872. doi:10.3390/jcm11164872.; Wittig T., Pflug T., Schmidt A., Scheinert D., Steiner S. Impact of Optimal Medical Therapy on Reintervention and Survival Rates after Endovascular Infrapopliteal Revascularization. J Clin Med. 2023;12(15):5146. doi:10.3390/jcm12155146.; Сумин А.Н., Медведева Ю.Д., Щеглова А.В., Барбараш Л.С. Пути снижения риска прогрессирования атеросклероза артерий нижних конечностей с позиции кардиолога. Комплексные проблемы сердечно-сосудистых заболеваний.2021;10(1):55-64. doi.10.17802/2306-1278-2021-10-1-55-64.; Thiney M., Della Schiava N., Feugier P., Lermusiaux P., Ninet J., Millon A., Long A. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease. Ann Vasc Surg. 2017;40:85-93. doi:10.1016/j.avsg.2016.08.030.; Howard R., Albright J., Powell C., Osborne N., Corriere M., Laveroni E., Sukul D., Goodney P., Henke P. Underutilization of medical management of peripheral artery disease among patients with claudication undergoing lower extremity bypass. J Vasc Surg. 2022;76(4):1037-1044.e2. doi:10.1016/j.jvs.2022.05.016.
-
15Academic Journal
Συγγραφείς: Karamova Y.S., Uskach T.M., Imaev T.E., Tereshchenko S.N.
Συνεισφορές: 1
Πηγή: Almanac of Clinical Medicine; Vol 52, No 2 (2024); 77-84 ; Альманах клинической медицины; Vol 52, No 2 (2024); 77-84 ; 2587-9294 ; 2072-0505
Θεματικοί όροι: heart failure, secondary mitral regurgitation, transcatheter mitral valve repair, clipping, drug therapy, remodeling, хроническая сердечная недостаточность (ХСН), вторичная митральная регургитация, транскатетерная пластика митрального клапана, оптимальная медикаментозная терапия, обратное ремоделирование
Περιγραφή αρχείου: application/pdf
Relation: https://almclinmed.ru/jour/article/view/17241/1657; https://almclinmed.ru/jour/article/view/17241/1662; https://almclinmed.ru/jour/article/view/17241/1667; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159861; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159862; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159965; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159966; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159967; https://almclinmed.ru/jour/article/downloadSuppFile/17241/159968; https://almclinmed.ru/jour/article/view/17241
-
16Academic Journal
Συγγραφείς: Matiash, M.M, Khudenko, L.I.
Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 3.97 (2018); 23-26
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 3.97 (2018); 23-26
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 3.97 (2018); 23-26Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, минно-взрывная закрытая черепно-мозговая травма, посттравматическое стрессовое расстройство, медикаментозная терапия, реабилитационные мероприятия, 05 social sciences, 0501 psychology and cognitive sciences, мінно-вибухова закрита черепно-мозкова травма, посттравматичний стресовий розлад, медикаментозна терапія, реабілітаційні заходи, mine blast closed craniocerebral injury, post-traumatic stress disorder, drug therapy, rehabilitation measures, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://inj.zaslavsky.com.ua/article/view/133678
-
17Academic Journal
Συγγραφείς: Goncharova, O.A.
Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 14, Iss 3, Pp 219-223 (2018)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 14, № 3 (2018); 219-223
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 3 (2018); 219-223
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 3 (2018); 219-223Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, Grave's disease, peripheral blood lymphocyte profile, drug therapy, дифузний токсичний зоб, медикаментозна терапія, лімфоцитарний профіль периферичної крові, RC648-665, диффузный токсический зоб, медикаментозная терапия, лимфоцитарный профиль периферической крови, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://iej.zaslavsky.com.ua/article/download/136415/135176
https://doaj.org/article/278fc178aa03485f8a579101a40426fe
http://iej.zaslavsky.com.ua/article/download/136415/135176
https://doaj.org/article/278fc178aa03485f8a579101a40426fe
http://iej.zaslavsky.com.ua/article/view/136415
http://iej.zaslavsky.com.ua/article/view/136415 -
18Academic Journal
Πηγή: Неврология и нейрохирургия. Восточная Европа. :211-224
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, медикаментозная терапия аналогами соматостатина и антагонистами СТГ-рецепторов, эндоскопическая эндоназальная транссфеноидальная хирургия, somatotropin-producing adenomas, medication therapy with somatostatin analogs and antagonists of STH receptors, pituitary adenomas, endoscopic endonasal trans-sphenoidal surgery, аденомы гипофиза, соматотропинпродуцирующие аденомы гипофиза, 3. Good health
-
19Academic Journal
Πηγή: Кардиология в Беларуси. :507-518
Θεματικοί όροι: tenecteplase, ЧКВ, фозиноприл, ОКС-инфаркт миокарда, пропранолол, fozinopril, heparin, 3. Good health, drug therapy, 03 medical and health sciences, 0302 clinical medicine, гепарин, медикаментозная терапия, ACS-myocardial infarction, propranolol, центральная гемодинамика, percutaneous coronary intervention (PCI), тенектеплаза, кардиогемодинамика и клиническое течение, central hemodynamics, cardiohemodynamics and clinical course
-
20Academic Journal
